Conducting a network meta-analysis is one of the most resource-intensive activities in the entire HEOR evidence generation pipeline, requiring significant manual effort across study identification, data extraction, statistical modelling, and evidence synthesis. The process often takes months, delaying updates in many therapeutic areas and creating operational bottlenecks that limit the timely availability of current comparative evidence. [4] For HEOR teams supporting EU JCA submissions, where NMA analyses are increasingly conducted on short timelines and against more complex multi-comparator evidence requirements, the traditional NMA timeline is no longer compatible with the submission clock.[7]
At Pienomial, we built KnolAI as our AI research platform specifically to address this bottleneck, applying intelligent automation across the most labour-intensive stages of network meta analysis AI pharma conduct without compromising the statistical rigour that NICE, G-BA, and ICER reviewers require. A 2026 ISPOR poster evaluating an AI-enabled NMA framework against six completed projects found the automated approach reproduced original NMA results with 100% accuracy, with time reductions of approximately 60 to 90% in early feasibility stages and 30 to 50% in reporting stages. [1] This post explains how to conduct a methodologically sound NMA with AI assistance and how KnolAI delivers this capability as part of the broader Knolens enterprise knowledge layer.[9]
Network meta-analysis is the statistical method that allows HEOR teams to compare multiple treatments simultaneously using both direct and indirect evidence across a connected network of randomised controlled trials, even when not every treatment pair has been directly compared in a head-to-head trial. [6] This capability is essential because most pharma submissions need to demonstrate comparative effectiveness against an HTA body-defined comparator that the pivotal trial did not directly test against.
The resource intensity of NMA conduct comes from four compounding manual tasks: study identification through a systematic literature review covering the full treatment network, data extraction of efficacy and safety outcomes from every included study with consistent definitions across heterogeneous trial designs, statistical modelling using Bayesian or frequentist NMA methods with appropriate heterogeneity and inconsistency assessment, and evidence synthesis producing the structured outputs, forest plots, league tables, and ranking probabilities, that the HTA submission requires. [2] Each of these tasks individually requires specialist expertise, and conducting them in sequence, the traditional workflow, is what produces the months-long timeline that current submission requirements increasingly cannot accommodate.[4]
Before any NMA can produce valid comparative estimates, the evidence network must be connected: every treatment in the network must be linked, directly or indirectly, to every other treatment through a chain of trials sharing common comparators. Testing this connectedness and quantifying the indirectness of each comparison, meaning how many steps in the network separate two treatments being compared, is a foundational methodological step that determines whether a specific comparison is even statistically valid.[5]
Graph theory techniques, including adjacency matrix construction and distance matrix calculation, provide an automatable way to test network connectedness and quantify indirectness systematically. [5] Each additional step of indirectness in a comparison requires further assumptions about homogeneity in trial design and target populations, which is precisely the kind of methodological judgement that HTA reviewers scrutinise closely. A rushed NMA that skips formal connectedness testing risks producing a comparison that is statistically generated but methodologically indefensible.
This is why AI-assisted NMA conduct, done correctly, accelerates the labour-intensive mechanical stages of NMA, study identification, data extraction, and structured reporting, while preserving and in some cases strengthening the methodological rigour of connectedness testing, heterogeneity assessment, and transitivity evaluation. Speed and rigour are not in tension when the automation is applied to the right stages of the workflow.[1]
KnolAI's NMA workflow, delivered through the Knolens platform, applies AI across the full NMA pipeline in five integrated stages, each building on the validated, sourced knowledge layer that underpins every KnolAI output.[9]
Stage 1, Treatment network identification: KnolAI identifies all relevant trials in the treatment network for the target indication from the Knolens knowledge layer, mapping every direct comparison that exists in the published and registered trial literature. This produces the initial network geometry: which treatments have been directly compared, and where the connectivity gaps exist that indirect comparison must bridge.
Stage 2, Connectedness and feasibility testing: KnolAI applies automated connectedness testing to the identified network, using the graph-theoretic methods that formally determine whether every treatment of interest is linked to every other through a valid evidence chain, and quantifies the indirectness, the number of steps, for each comparison the submission requires. [5] This produces a feasibility assessment before any statistical modelling begins, identifying which comparisons the available evidence network can support and which require either a different network structure or supplementary evidence.
Stage 3, Structured data extraction with source attribution: For every study in the feasible network, KnolAI extracts the efficacy and safety outcome data required for the NMA model, with sentence-level source attribution linking every extracted figure to its specific location in the source publication. This is the stage where AI delivers the most dramatic time compression: the ISPOR 2026 framework evaluation found 60 to 90% time reductions specifically in this data harmonisation and validation stage.[1]
Stage 4, Heterogeneity and transitivity assessment: KnolAI assesses clinical and methodological heterogeneity across the included trials, covering population characteristics, intervention definitions, comparator definitions, and outcome measurement approaches, flagging any heterogeneity that may threaten the transitivity assumption underlying the indirect comparisons. This assessment is presented with full documentation for HEOR statistician review before the formal statistical model is finalised.[2]
Stage 5, Statistical modelling and structured reporting: The NMA statistical model, whether Bayesian or frequentist, is executed using established, validated statistical methodology, with KnolComposer generating the structured reporting outputs: forest plots, league tables, treatment ranking probabilities, and the full methodology documentation required for NICE DSU Technical Support Document compliance or equivalent HTA body methodology standards.[9]
The most important finding from the 2026 ISPOR evaluation of an AI-enabled NMA framework is not the speed improvement alone. It is that the AI-enabled framework reproduced original NMA results with 100% accuracy across all six evaluated projects, meaning the automated approach did not trade accuracy for speed. [1] The estimated time reductions, 60 to 90% in early feasibility stages including data harmonisation and validation, and 30 to 50% in reporting stages, were achieved without any compromise in the statistical validity of the final comparative estimates.
This finding matters directly for how HEOR teams should think about deploying AI in NMA conduct: the value of AI automation is concentrated in the stages that are mechanical and repetitive, study identification, data harmonisation, and structured reporting, not in replacing the statistical judgement that an experienced biostatistician applies to model selection, heterogeneity interpretation, and sensitivity analysis design. KnolAI is built around exactly this division of labour: AI accelerates the mechanical stages and surfaces the methodological considerations that require human statistical judgement, with the HEOR biostatistician retaining full control over model specification and interpretation.[3]
A particular challenge for HEOR teams preparing multi-HTA submissions is that NICE, G-BA, and ICER each apply different methodology preferences to NMA reporting. NICE follows NICE DSU Technical Support Document guidance, generally preferring Bayesian NMA with full probabilistic sensitivity analysis and explicit uncertainty characterisation. G-BA accepts adjusted indirect comparisons where full NMA is not feasible, with strict heterogeneity documentation requirements and relative treatment effects expressed as hazard ratios with 95% confidence intervals. ICER accepts NMA with sensitivity analyses and explicit discussion of network limitations.[9]
KnolAI structures the underlying NMA from a single evidence network and dataset, then generates the methodology presentation and statistical reporting format appropriate to each target HTA body from that same underlying analysis. The treatment network, the extracted data, and the core statistical model are identical across all body-specific outputs. Only the presentation format, language, and supplementary sensitivity analyses required by each body differ. This is the same shared evidence layer principle that underpins all multi-HTA work on the Knolens platform: one analysis, multiple compliant presentations, with guaranteed factual consistency across all of them.
A growing application of AI in NMA conduct is the integration of NMA effect estimates with observational real-world data, allowing for more thorough consideration of individual patient characteristics and improved control for sources of bias that pure RCT-based NMA cannot address. [3] This is particularly valuable when the trial network does not adequately represent the real-world patient population the HTA body will be assessing reimbursement for.
KnolAI supports this integration by drawing real-world evidence sources into the same knowledge layer that powers the trial-based NMA, enabling population-adjusted indirect comparison methods such as matching-adjusted indirect comparison or simulated treatment comparison when patient-level data access permits, or RWE-anchored sensitivity analyses that test how the NMA results would shift under real-world population characteristics. This capability directly addresses the evidence gap that occurs when a trial network is methodologically sound but clinically narrower than the population the payer needs reassurance about.[9]
Five methodology pitfalls consistently undermine NMA credibility in HTA submissions, and AI-assisted workflows specifically address each of them through systematic, documented process rather than relying on individual analyst diligence under time pressure.[2]
Pitfall 1, Undetected network disconnection: A treatment comparison is presented without a valid connected evidence path. KnolAI's automated connectedness testing catches this before statistical modelling begins, rather than after a reviewer identifies an invalid comparison post-submission.[5]
Pitfall 2, Unaddressed heterogeneity: Trials with materially different patient populations or outcome definitions are pooled without adequate heterogeneity assessment. KnolAI's automated heterogeneity flagging surfaces these differences systematically across every included study, not just the ones an analyst happens to notice.
Pitfall 3, Inconsistent data extraction: The same outcome is extracted with different definitions or time points across different studies in the network, undermining comparability. KnolAI's structured extraction applies consistent definitions across the full evidence set with source-level documentation of any definitional variation encountered.
Pitfall 4, Insufficient transitivity discussion: The submission does not adequately document why the transitivity assumption, that indirect comparisons are valid given the trial differences, is reasonable for the specific network. KnolAI generates structured transitivity assessment documentation as a standard output, not an optional addition.[2]
Pitfall 5, Outdated network at submission: New trials completed during the months-long traditional NMA timeline are not incorporated before the network is finalised. Because KnolAI compresses the timeline dramatically and connects to the Knolens living evidence base, the NMA reflects the trial landscape as it exists at submission, not as it existed when data extraction began months earlier.[9]
Every stage of the KnolAI NMA workflow generates audit trail documentation that satisfies the methodology transparency requirements NICE, G-BA, and ICER apply to AI-assisted evidence synthesis. The audit trail covers the search strategy used to identify the treatment network, the connectedness and feasibility testing results, the source-attributed extraction for every data point included in the model, the heterogeneity and transitivity assessment, and the statistical modelling specification including all sensitivity analyses conducted.[9]
This documentation satisfies NICE's 2024 position statement requirement for transparent reporting of AI-assisted evidence generation, including PALISADE and TRIPOD+AI checklist completion, and provides the reproducibility documentation that a NICE technical team or G-BA scientific reviewer requires to independently verify the NMA methodology. For HEOR teams, the practical benefit is that the methodology documentation that traditionally requires substantial additional analyst time to prepare separately from the analysis itself is generated automatically as a by-product of the KnolAI workflow.
Building network meta analysis AI pharma capability with KnolAI does not require months of statistical infrastructure development. KnolAI's NMA workflow is a pre-built capability within the Knolens platform, configurable to your indication and evidence requirements from the first sprint.[9]
Sprint 1, Weeks 1 to 2, Treatment network identified and feasibility tested: KnolAI identifies the relevant trial network for your indication and target comparators from the Knolens knowledge layer. Automated connectedness testing and indirectness quantification produce the feasibility assessment, identifying which comparisons the available evidence supports before any statistical modelling investment is made.
Sprint 2, Weeks 3 to 4, Data extraction and heterogeneity assessment complete: Structured, source-attributed extraction runs across the full feasible network. Heterogeneity and transitivity assessment is generated and reviewed by your HEOR biostatistics team. This is the stage where the ISPOR 2026 evaluation documented the largest time reduction, 60 to 90% versus manual data harmonisation.[1]
Sprint 3, Weeks 5 to 6, Statistical model executed and multi-body reporting generated: The NMA statistical model is finalised with your biostatistics team's specification and sensitivity analyses. KnolComposer generates the body-specific structured reporting outputs, forest plots, league tables, and methodology documentation, formatted for each target HTA body from the single underlying analysis.[9]
Network meta-analysis is too important to a pharma submission's comparative effectiveness case to be rushed, and too resource-intensive under traditional manual methods to be completed within the timelines that EU JCA and rapid HTA pathways increasingly demand. The evidence from the 2026 ISPOR framework evaluation is clear: AI-assisted NMA conduct can deliver 100% reproduction accuracy alongside 60 to 90% time reductions in the most labour-intensive stages, when the automation is applied to the right parts of the workflow.
At Pienomial, we built KnolAI's network meta analysis AI pharma capability to deliver exactly this combination: methodological rigour preserved and strengthened through systematic, documented automated processes, and timeline compression that brings NMA conduct in line with the speed that modern HTA submission requirements demand. [9] CTA: See how KnolAI accelerates network meta-analysis without compromising rigour. Book a demo with the Pienomial team.
